LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) $ in Thousands		1 Months Ended							3 Months Ended		12 Months Ended					66 Months Ended	72 Months Ended	98 Months Ended
	Oct. 01, 2014 USD ($)	Jun. 30, 2014 USD ($)	Apr. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Aug. 31, 2012 USD ($)	Nov. 30, 2008 item	Jul. 31, 2008 USD ($)	Jul. 31, 2005 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2016 USD ($) item	Dec. 31, 2016	Dec. 31, 2016 USD ($) item
License arrangements
Revenue recognized													$ 31,515
Royalty revenue											$ 831	$ 985	1,821
Mallinckrodt, Inc.
License arrangements
Number of products to be developed by utilizing Acuform technology | item						4
Number of products elected to develop | item						2
Upfront fees and milestones payment received																		$ 27,500
Upfront fee received																		4,000
Upfront fee received for formulation work to be performed under the agreement																		$ 1,500
Number of milestone payments received | item																		4
Clinical development milestone payments																		$ 500
Milestone payments following FDA's Acceptance											$ 10,000							$ 5,000
Milestone payment received		$ 5,000	$ 10,000
Revenue recognized													15,000
Milestone revenue recognized				$ 1,000					$ 5,000	$ 10,000
Janssen Pharmaceutica N.V.
License arrangements
Upfront fee received					$ 10,000
Ironwood Pharmaceuticals, Inc.
License arrangements
Upfront fees, initial product formulation work and milestone payments received																$ 3,400
Number of milestone payments received | item																3
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Commercialization Agreement
License arrangements
Revenue recognized													$ 3,000	$ 1,400	$ 3,300
Royalties on net product sales, percentage in 2011																	26.50%
Royalties on net product sales, percentage in 2012															29.50%
Royalties on net product sales, percentage in 2013 and 2014													32.00%	32.00%
Royalties on net product sales, percentage in 2015 and beyond												34.50%
Royalty revenue														$ 42,100	$ 42,800
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Promotion Agreement
License arrangements
Upfront fee received							$ 12,000
Revenue recognized	$ 1,900
Valeant Pharmaceuticals International, Inc.
License arrangements
Upfront fee received								$ 25,000
Revenue recognized													$ 12,500	$ 1,600	$ 1,600
Valeant Pharmaceuticals International, Inc. | 1000mg Glumetza
License arrangements
Revenue recognized	$ 11,300